Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 20
- Registration Number
- NCT06730542
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT06682169
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
Optimizing Treatment for Patients with Juvenile Idiopathic Arthritis in Sustained Remission: the MOVE-JIA Trial
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06653634
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
🇳🇴Haukeland University Hospital, Bergen, Norway
🇳🇴Drammen Hospital, Drammen, Norway
MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients with Active Rheumatoid Arthritis
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 182
- Registration Number
- NCT06649136
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Local Methotrexate Injections for the Treatment of Nail Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 10
- Registration Number
- NCT06578728
- Locations
- 🇺🇸
Israel Englander Department of Dermatology, New York, New York, United States
Effect of MTX Discontinuation on Shingrix Response in RA
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 110
- Registration Number
- NCT06574594
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 43
- Registration Number
- NCT06554561
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06554626
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06541665
- Locations
- 🇯🇵
Kindai University Hospital, Osakasayama-shi, Osaka, Japan
🇯🇵Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵National Hospital Organization Disaster Medical Center, Midori-cho, Tokyo, Japan
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06533748
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.